Literature DB >> 17455553

Cardiac denervation in patients with Parkinson disease.

David S Goldstein1.   

Abstract

More than 40 neuroimaging studies have reported evidence for loss of sympathetic noradrenergic nerves in PD. Cardiac sympathetic denervation is virtually universal in patients with PD and neurogenic orthostatic hypotension. About one half of patients with PD who do not have orthostatic hypotension also have evidence for loss of noradrenergic innervation. The loss progresses over years, in a pattern suggesting "dying-back". Because patients with familial PD from mutation of the gene encoding alpha-synuclein or from triplication of the normal gene have low myocardial concentrations of 6-[18F]fluorodopamine-derived radioactivity, cardiac sympathetic denervation seems linked etiologically with alpha-synucleinopathy. Baroreflex-cardiovagal failure and cardiac sympathetic denervation can occur before onset of the movement disorder, suggesting that neurocardiologic testing might provide a biomarker for detecting presymptomatic or early PD and for following responses to putative neuroprotective treatments.

Entities:  

Mesh:

Year:  2007        PMID: 17455553     DOI: 10.3949/ccjm.74.suppl_1.s91

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  19 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 2.  Cardiac sympathetic denervation imaging in movement disorders and dementias.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

3.  Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes.

Authors:  C Friedrich; H Rüdiger; C Schmidt; B Herting; S Prieur; S Junghanns; K Schweitzer; C Globas; L Schöls; D Berg; H Reichmann; T Ziemssen
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

4.  Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension.

Authors:  T Pérez; B Tijero; I Gabilondo; A Luna; V Llorens; K Berganzo; M Acera; A Gonzalez; A Sanchez-Ferro; E Lezcano; J J Zarranz; J C Gómez-Esteban
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

5.  Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease.

Authors:  Yehonatan Sharabi; David S Goldstein
Journal:  J Neurol Sci       Date:  2011-07-16       Impact factor: 3.181

6.  Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-12

7.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

Review 8.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 9.  Parkinson's disease and pesticides: a toxicological perspective.

Authors:  Jaime M Hatcher; Kurt D Pennell; Gary W Miller
Journal:  Trends Pharmacol Sci       Date:  2008-04-29       Impact factor: 14.819

Review 10.  Neurogenic orthostatic hypotension: a pathophysiological approach.

Authors:  David S Goldstein; Yehonatan Sharabi
Journal:  Circulation       Date:  2009-01-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.